|
CERS | Cerus Corp |
|
|
CERS | Cerus Corp |
| Surgical & Medical Instruments & Apparatus |
| Book value per $ invested | $ 0.14 |
| Leverage | 65.54% |
| Market Cap | $ 505.8m |
| PE | 0.00 |
| Dividend Yield | 0.00% |
| Profit | $ -6.8m |
| Margin | -3.91% |
Cerus Corporation, a biomedical products company, is focused on developing and commercializing the INTERCEPT Blood System to improve blood safety. The company is headquartered in Concord, California.